Emerging evidence on oral contraceptives and arterial disease

Contraception

Volumn 62, Issue 2 SUPPL. 1, 2000, Pages

  Heinemann, Lothar A J ^a  

^a Berlin Center for Epidemiology and Health Research   (Germany)

Author keywords

Myocardial infarction; Oral contraceptives; Risk factors; Stroke; Venous thromboembolism

Indexed keywords

DESOGESTREL; ESTROGEN; GESTAGEN; GESTODENE; NORGESTREL; ORAL CONTRACEPTIVE AGENT;

CARDIOVASCULAR RISK; CONFERENCE PAPER; DRUG SAFETY; FEMALE; HEART INFARCTION; HUMAN; ORAL CONTRACEPTION; STROKE; THROMBOEMBOLISM;

ADULT; BIAS (EPIDEMIOLOGY); CEREBROVASCULAR ACCIDENT; CONTRACEPTIVES, ORAL; FEMALE; HUMANS; MIDDLE AGED; MYOCARDIAL INFARCTION; RISK FACTORS; VASCULAR DISEASES; VENOUS THROMBOSIS;

EID: 0033693149     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0010-7824(00)00146-3     Document Type: Conference Paper

References (61)

1. Oral contraceptives and cardiovascular disease; an epidemiologic overview
2. Transnational Research Group on Oral Contraceptives and the Health of Young Women. Third generation oral contraceptives and risk of venous thromboembolic disorders; an international case-control study
3. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components
4. Oral contraceptive use and venous thromboembolism; a consideration of the impact of bias and confounding factors on epidemiological studies
5. The 1995 pill scare revisited; anatomy of a non-epidemic
6. Oral contraceptive estrogen dose and risk of deep venous thromboembolic disease
7. Oral contraceptives and venous thromboembolism; findings in a large prospective study
8. Comparison of two triphasic contraceptives with different progestogens; effects on metabolism and coagulation proteins
9. Lipid metabolism and coagulation of two contraceptives; correlation to serum concentrations of levonorgestrel and gestodene
10. A comparative study on the effects of a monophasic pill containing desogestrel plus 20 μg ethinylestradiol, a triphasic combination containing levonorgestrel and a monophasic combination containing gestodene on coagulatory factors
11. Metabolic changes during treatment with two different progestogens
12. A concurrent cohort study of oral contraceptive users from the VAMP research bank
13. Could preferential prescribing and referral behaviour of physicians explain the elevated thrombosis risk found to be associated with third-generation oral contraceptives?
14. Oral contraceptive switching patterns in the United Kingdom; an important potential confounding variable in studies of venous thromboembolism
15. Utilization patterns of oral contraceptives in UK general practice
16. Recent oral contraceptive use patterns in four European countries; evidence for selective prescribing of oral contraceptives containing third generation progestogens
17. Selective prescribing of third generation oral contraceptives (OCs)
18. The increased risk of venous thromboembolism and the use of third generation progestagens; role of bias in observational research
19. Population-based study of venous thromboembolism associated with various oral contraceptives
20. The influence of thrombotic risk factors when oral contraceptives are prescribed. A control only study
21. The role of prescribing and referral bias in studies of the association between third generation oral contraceptives and increased risk of thromboembolism
22. Parietal lesion and Enovid
23. Investigation of relation between use of oral contraceptives and thromboembolic disease. A further report
24. Thromboembolism and oral contraceptives; an epidemiologic case-control study
25. Ischaemic cerebrovascular disease in young adults
26. Oral contraceptives and non-fatal stroke in healthy young women
27. Fatal stroke and use of oral contraceptives; findings from a case-control study
28. Oral contraception and risk of a cerebral thromboembolic attack; results of a case-control study
29. Incidence of arterial disease among oral contraceptive users
30. Oral contraceptives and stroke; findings in a large prospective study
31. Orale Kontrazeptiva-Riosikofaktoren fur Herz-Kreislauf-Ereignisse-zufallige Assoziation oder Kausale Beziehung
32. Internationale epidemiologische Studien zum kardiovaskularen Risiko hormonaler Kontrazeption
33. Stroke in users of low-dose oral contraceptives
34. Cerebral thrombosis and oral contraceptives
35. Use of low-dose oral contraceptives and stroke in young women
36. Is the stroke risk in OC users higher in Europe than in North America?
37. Myocardial infarction and angina pectoris in young women
38. Risk factors for acute myocardial infarction in women; evidence from the Royal College of General Practitioners' oral contraception study
39. Is oral contraceptive use still associated with an increased risk of fatal myocardial infarction? Report of a case-control study
40. Lowered risk of dying of heart attack with third generation pill may offset risk of dying of thromboembolism
41. Risk of acute myocardial infarction and low-dose combined oral contraceptives
42. Oral contraceptives and acute myocardial infarction; a case-control study
43. Structural requirements for optimal receptor binding of contraceptive progestogens
44. Relation between sex hormone binding globulin and d-norgestrel levels in plasma
45. Serum steroid levels, sex-hormone-binding globulin, and body mass index in the etiology of postmenopausal breast cancer
46. Pathogenesis of vascular disease in oral contraceptive users